Inhaled drug combo aims to boost lung cancer treatment before surgery
NCT ID NCT06694454
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 35 times
Summary
This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage IB-IIIA NSCLC. Participants receive the inhaled drug for three days each cycle, plus IV chemo and immunotherapy, followed by tumor removal surgery. The goal is to find the safest and most effective dose and see if this combination can eliminate all cancer cells in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inhaled azacytidine (a drug that affects gene activity) combined with standard chemotherapy (carboplatin and paclitaxel) and durvalumab (an immunotherapy)
- What this could lead to
- If it works, this could lead to a new treatment option that helps shrink early-stage lung cancer before surgery, potentially reducing the chance of the cancer coming back.
- What could go wrong
- This is an early-phase trial with only 60 people, so the benefits are not proven yet. The inhaled drug is experimental for lung cancer, and side effects from the combination therapy could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a targeted pill keep lung cancer from returning?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?